Follicular lymphoma natural history, complications and prognosis

Follicular lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Follicular lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-Ray
CT scan
MRI
Echocardiography or Ultrasound
Biopsy
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Follicular lymphoma natural history, complications and prognosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Follicular lymphoma natural history, complications and prognosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Follicular lymphoma natural history, complications and prognosis
CDC on Follicular lymphoma natural history, complications and prognosis
Follicular lymphoma natural history, complications and prognosis in the news
Blogs on Follicular lymphoma natural history, complications and prognosis
Directions to Hospitals Treating Follicular lymphoma
Risk calculators and risk factors for Follicular lymphoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Overview

Prognosis is generally poor and the 5 year survival rate of patients with follicular lymphoma is approximately 72-77%.

Prognosis

• Follicular lymphoma is regarded as incurable (although allogenic stem cell transplantation may be curative, the mortality from the procedure is too high to be a first line option). The median survival is around 10 years, but the range is wide, from less than one year, to more than 20 years. Some patients may never need treatment. The overall survival rate at 5 years is 72-77%.
• The following factors are associated with poor prognosis:.

• Grade 3 histopathologic grading
• Presence of cytogenic abnormalities of BCL-6 gene